Thomas M. Haas

Array ( [id] => 19556462 [patent_doc_number] => 20240368254 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-11-07 [patent_title] => ACCELERATED METHOD OF MAKING LYOPHILIZED PROTEIN FORMUALTIONS [patent_app_type] => utility [patent_app_number] => 18/561081 [patent_app_country] => US [patent_app_date] => 2022-06-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14028 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -39 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18561081 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19297745 [patent_doc_number] => 20240226311 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-07-11 [patent_title] => Improved immunoglobulin II [patent_app_type] => utility [patent_app_number] => 18/561040 [patent_app_country] => US [patent_app_date] => 2022-05-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20296 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18561040 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19331342 [patent_doc_number] => 20240245772 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-07-25 [patent_title] => BI-SPECIFIC CHIMERIC ANTIGEN RECEPTORS AND GENETICALLY ENGINEERED IMMUNE CELLS EXPRESSING SUCH [patent_app_type] => utility [patent_app_number] => 18/561307 [patent_app_country] => US [patent_app_date] => 2022-05-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20427 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -42 [patent_words_short_claim] => 65 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18561307 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19281558 [patent_doc_number] => 20240218032 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-07-04 [patent_title] => NOVEL HUMAN PROGRAMMED DEATH LIGAND 1 (PD-L1) SPECIFIC BINDING MOLECULES [patent_app_type] => utility [patent_app_number] => 18/556860 [patent_app_country] => US [patent_app_date] => 2022-04-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11480 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18556860 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19246891 [patent_doc_number] => 20240197875 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-20 [patent_title] => NOVEL METHOD [patent_app_type] => utility [patent_app_number] => 18/554501 [patent_app_country] => US [patent_app_date] => 2022-04-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10865 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -50 [patent_words_short_claim] => 53 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18554501 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19170897 [patent_doc_number] => 20240156871 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-16 [patent_title] => CYTOKINE-INDUCED KILLER CELLS [patent_app_type] => utility [patent_app_number] => 18/550832 [patent_app_country] => US [patent_app_date] => 2022-03-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3779 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 23 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18550832 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19172529 [patent_doc_number] => 20240158503 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-16 [patent_title] => ANTI-VSIG4 ANTIBODY OR ANTIGEN BINDING FRAGMENT AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/280068 [patent_app_country] => US [patent_app_date] => 2022-03-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37040 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 79 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18280068 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17960068 [patent_doc_number] => 20220340648 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-10-27 [patent_title] => ANTI-ALPHA-SYNUCLEIN ANTIBODIES [patent_app_type] => utility [patent_app_number] => 17/682082 [patent_app_country] => US [patent_app_date] => 2022-02-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27767 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17682082 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17790460 [patent_doc_number] => 20220249551 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-11 [patent_title] => STIMULATION OF NATURAL KILL CELL MEMORY BY ADMINISTRATION OF DENDRITIC CELLS [patent_app_type] => utility [patent_app_number] => 17/667349 [patent_app_country] => US [patent_app_date] => 2022-02-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6415 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 66 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17667349 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19067221 [patent_doc_number] => 20240101647 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-28 [patent_title] => SARBECOVIRUS BINDERS [patent_app_type] => utility [patent_app_number] => 18/275986 [patent_app_country] => US [patent_app_date] => 2022-02-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 54579 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18275986 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19067239 [patent_doc_number] => 20240101665 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-28 [patent_title] => MONOCLONAL ANTIBODY AGAINST HUMAN GPR48 AND APPLICATION THEREOF [patent_app_type] => utility [patent_app_number] => 18/263883 [patent_app_country] => US [patent_app_date] => 2022-01-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9738 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18263883 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19432552 [patent_doc_number] => 20240301050 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-12 [patent_title] => NOVEL BINDING MOLECULE AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/263210 [patent_app_country] => US [patent_app_date] => 2022-01-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19588 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18263210 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19032578 [patent_doc_number] => 20240082393 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-14 [patent_title] => ADJUVANTS TO STIMULATE BROAD AND PERSISTENT INNATE IMMUNITY AGAINST DIVERSE ANTIGENS [patent_app_type] => utility [patent_app_number] => 18/270996 [patent_app_country] => US [patent_app_date] => 2022-01-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29263 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18270996 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19418488 [patent_doc_number] => 20240294611 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-05 [patent_title] => CROSS-REACTIVE ANTIBODIES RECOGNIZING THE CORONAVIRUS SPIKE S2 DOMAIN [patent_app_type] => utility [patent_app_number] => 18/260891 [patent_app_country] => US [patent_app_date] => 2022-01-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 50370 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -88 [patent_words_short_claim] => 78 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18260891 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19034224 [patent_doc_number] => 20240084039 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-14 [patent_title] => ANTIBODY VARIABLE DOMAINS AND ANTIBODIES HAVING DECREASED IMMUNOGENICITY [patent_app_type] => utility [patent_app_number] => 18/258957 [patent_app_country] => US [patent_app_date] => 2021-12-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28952 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 268 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18258957 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18953696 [patent_doc_number] => 20240042023 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-08 [patent_title] => Fc-Receptor CAR Constructs and Cells [patent_app_type] => utility [patent_app_number] => 18/258925 [patent_app_country] => US [patent_app_date] => 2021-12-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8095 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18258925 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19020229 [patent_doc_number] => 20240076400 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-07 [patent_title] => EPCAM BINDING MOLECULES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/258200 [patent_app_country] => US [patent_app_date] => 2021-12-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13739 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18258200 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18987797 [patent_doc_number] => 20240059766 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-22 [patent_title] => TAU BINDING COMPOUNDS [patent_app_type] => utility [patent_app_number] => 18/267711 [patent_app_country] => US [patent_app_date] => 2021-12-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 50796 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -33 [patent_words_short_claim] => 23 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18267711 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17776837 [patent_doc_number] => 20220243186 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-04 [patent_title] => FUSION PROTEIN FOR NATURAL KILLER CELL SPECIFIC CRISPR/CAS SYSTEM AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/544429 [patent_app_country] => US [patent_app_date] => 2021-12-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10627 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17544429 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18877467 [patent_doc_number] => 20240000836 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-04 [patent_title] => BCMA-TARGETED CAR-T CELL THERAPY FOR MULTIPLE MYELOMA [patent_app_type] => utility [patent_app_number] => 18/039420 [patent_app_country] => US [patent_app_date] => 2021-12-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 53404 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -125 [patent_words_short_claim] => 111 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18039420 [rel_patent_id] =>[rel_patent_doc_number] =>)